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Normal Fibrinolytic Responses to 
1 -Desamino-8-O-Arginine Vasopressin 
in Patients with Nephrogenic Diabetes 
insipidus Caused by Mutations in the 
Aquaporin 2 Gene
Abstract
Three patients with autosomal-recessive nephrogenic diabetes insipidus 
(NDI), homozygous for mutations in the aquaporin 2 gene (AQP2), were 
tested for their fibrinolytic and hemodynamic responses to intravenous
adm inistration of l-desamino-8-D-arginine vasopressin (DDAVP). They all 
showed an increase of tissue-type plasminogen activator antigen, facial flush­
ing, an increase of heart rate and a decrease of diastolic blood pressure. These 
results confirm the hypothesis that NDI patients with an AQP2 delect can be 
discrim inated from NDI patients with a vasopressin type 2 receptor defect by 
their normal extrarenal responses to DDAVP.
Introduction polydipsia and an increased risk of dehydration. Further­
more, most NDI patients lack the extrarenal responses to 
The m ain functions of the neurohypophyseal horm one DDAVP, indicating a generalized V2 receptor defect [3, 
arginine vasopressin (AVP) are reflected by its two names; 7-9]. Evidence for the hypothesis that a V2 receptor 
‘vasopressin’ refers to the vasoconstriction resulting from defect causes NDI was gained when m utations in the V2 
binding to vasopressin type 1 receptors on vascular receptor gene were found in patients with the X-linked 
smooth muscle cells, while ‘antidiuretic horm one’ desig- recessive form of the disease [ 10]. Some patients have 
nates the urinary concentration occurring in response to been reported, however, who showed normal fibrinolytic, 
binding to vasopressin type 2 (V2) receptors in the renal coagulation and hemodynamic responses to DDAVP, in­
collecting ducts. Strong activation of the V2 receptor can dicating that their extrarenal V2 receptor functions nor- 
be accomplished by adm in istra tion  of l-desam ino-8-.D- mally [11-13]. The observation that, in these patients, 
arginine vasopressin (DDAVP), a V2 receptor agonist only the renal response to DDAVP is impaired, can be 
with an an tid iuretic /pressor ratio o f 4,000 [ 1 ]. In addition explained by the presence of a defect in the antidiuretic
to its renal antid iuretic  action, D D A V P elicits vasodila­
tion and an increase o f coagulation and fibrinolysis fac-
AVP pathway beyond the V2 receptor. Recently, the gene 
was cloned which encodes the aquaporin 2 (AQP2) water 
tors [2, 3]. T he exact location o f the V2 receptors which channel, a protein that is inserted into the apical mem- 
m ediate these effects is unknow n. Studies in anephric brane of collecting duct cells in response to activation of 
subjects have excluded the possibility that they are situ- the V2 receptor [14]. The first patient in which we 
ated in the kidney [2, 4], M oreover, evidence supporting observed a normal extrarenal response to DDAVP was 
the presence o f V2 receptors on monocytes has been demonstrated to be a compound heterozygote for muta- 
gained [5, 6], H ereditary  nephrogenic diabetes insipidus tions in this autosomal AQP2 gene, a finding which con- 
(NDI) is a rare disease in which the antidiuretic response firmed the postulated presence of a renal post-V2-recep- 
to AVP and D D A V P is lacking, resulting in polyuria, tor defect [15]. Since this is the onlv patient with a proven
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AQP2 defect whose extra-renal responses to DDAVP 
have been studied, we performed DDAVP tests in 3 addi­
tional patients with distinct AQP2 mutations, with the 
objective of confirming the assumption that in these N D I 
patients extrarenal responses to DDAVP are normal.
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Methods
Patients
DDAVP tests were performed in 3 NDI patients in whom hom o­
zygosity for an AQP2 mutation had been detected by sequencing 
analysis (table I ). All patients gave informed consent prior to the test. 
A detailed description of the case histories, DNA analysis and in 
vitro expression o f the m utations has been given in a previous report 
[16]. Patients 1 and 3 did not take any medication. Patient 2, who 
used amiloride-hydrochlorothiazide 2 times a day, discontinued 
medication 12 h prior to the test.
DDA VP Tests
Food and water were not restricted before or during the test. After 
cannulation of a cubital vein, patients rested for 50 inin in the recum­
bent position. From t = 0 to t = 10, a dose o f 0.3 jig DDAVP (Min- 
rin®, Fcrring, Malmo, Sweden) per kg body weight, diluted in 100 ml 
NaCl 0.9%, was infused. Systolic and diastolic blood pressure and 
heart rate were monitored at 3-min intervals during the first 25 min 
and at 10-min intervals thereafter. Blood samples were taken from 
the indwelling venipuncture 10 min before (t = - 10), immediately 
before (t = 0) and 10, 20, 30 and 60 min after the start of the DDAVP 
infusion. Each time the first 4 ml o f blood were discarded. The next 
4.5 ml were collected in a new syringe and transferred into tubes con­
taining 0.5 ml 3.8% sodium citrate. The tubes were immediately 
cooled on melting ice. Platelet-poor plasma obtained by centrifuga­
tion at 4 °C  for 10 min at 3 ,000&  was quickly frozen in aliquots o f 
0.5 ml and stored at -7 0  °C until assays were performed. Tissue-type 
plasminogen activator antigen (tPA:Ag) was measured by an en- 
zyme-1 inked immunoassay (Innotest, Chromogcnix, Zwijndrecht, 
Belgium). Data were compared with those obtained from 6 N D I 
patients [3] in whom a V2 receptor gene mutation had been found.
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Fig. 1. Tissue-type plasm inogen activator antigen response 
(tPA:Ag) to D D A V P in the 3 patien ts  studied ( •  = patient 1; À = 
patient 2; T  = patient 3). M ean  and SEM values o f 6 N D I patients [3] 
with a V2 receptor m utation  (x) are shown as well. tPA:Ag values at 
t = 0 are expressed as 100%.
Table 1. D ata  on N D I patien ts  w ith  an A Q P2 defect
Patient No. Age, years Sex M utation
1 29 M A rgi87Cys
2 25 F Gly64Arg
3 18 M C369del
Discussion
Results
Two genetically distinct forms o f  hereditary N D I are 
currently known to exist; X-linked N D I is caused by 
mutations in the V2 receptor gene, autosomal-recessive 
NDI results from m utations in the A QP2 gene. The clini­
cal phenotype in these two categories of patients seems 
identical [16], rendering discrim ination between the two 
In the 3 patients with an AQP2 defect, a significant rise forms on this basis impossible. Observations m ade in the 
of tPA:Ag values occurred in response to the DDAVP first-described AQP2-NDI patient, however, suggested 
administration. The intensity and time course of the that these patients may be distinguished from patients 
responses varied, but the pattern was clearly distinct from with a V2 receptor defect by m eans o f their extrarenal
those obtained in patients with a V2 receptor defect responses to DDAVP [12, 15]. T he present study con-
(fig. 1). Furthermore, a few minutes after the start of the firms this hypothesis by dem onstrating an increase of
DDAVP infusion, an increase of heart rate, varying from tPA:Ag and heart rate, a decrease o f diastolic blood pres-
29 to 48% compared to the baseline heart rate (t = 0), and sure and the occurrence o f  a facial flush in 3 additional
a facial Hush were observed. During the DDAVP infu- N D I patients with an AQP2 defect. D iscrim ination of the
sion, all patients showed a decrease of diastolic blood two subgroups of N D I patients on the basis o f  a DDAVP
pressure (15-22%) compared to the baseline value. No test is useful in families in which only 1 patient or several
significant decrease of systolic blood pressure was ob- siblings are affected, since in these families the nature of
served (3-9%) (data not shown). the genetic defect cannot be inferred from  the pattern of
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inheritance. In these families, results o f the test permit a 
more efficient approach for DNA analysis. Moreover, in 
circumstances where facilities for DNA analysis are lack­
ing, they may provide the sole basis for genetic counselling.
W hen perform ed in female patients, in terpretation of 
the test is more complicated. Although in female patients 
an AQP2 defect seems obvious, we observed a phenotype 
similar to the phenotype o f male N D I patients, including 
absence of the extrarenal response to D D A V P, in female 
carriers of a V2R m utation  [17]. A plausible explanation 
for this phenom enon is p redom inan t inactivation of the 
X-chrom osom e carrying the norm al V 2R  allele in both 
renal collecting duct cells and cells m ediating the extra- 
renal response to DDAVP. Since patterns of X-inactiva- 
tion have been described to vary between different tissues 
[17], it is possible that the extrarenal response to DDAVP 
is normal in some o f the sym ptom atic female carriers of a 
V2 receptor m utation. This could be the case, for in­
stance, in the female patients described by Brenner et al.
[11] and Moses et al. [18]. Therefore, it seems hazardous 
to discriminate female N D I patients homozygous for an 
AQP2 mutation from female patients hemizygous for a 
V2 receptor gene mutation on the basis of a normal 
extrarenal DDAVP test. Absence of this response, how­
ever, appears to be a distinguishing feature.
In conclusion, normal extrarenal responses to DDAVP 
have now been demonstrated in 4 NDI patients with a 
proven AQP2 defect, thereby confirming that this test can 
discriminate between male AQP2 patients and male V2 re­
ceptor patients. In female patients with a normal response, 
however, the possibility that hemizygosity for a V2 receptor 
mutation causes the disease needs to be considered.
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